---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-26-000012"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:10:02.603101+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Caribou gets RMAT designation from FDA for CB-011 in relapsed/refractory multiple myeloma

## Summary
- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for CB-011 allogeneic anti-BCMA CAR-T.
- RMAT based on CaMMouflage phase 1 dose escalation data: 92% ORR, 75% ≥CR, 91% MRD negativity in 12 BCMA-naïve patients at RDE.
- No graft-versus-host disease or certain neurotoxicities observed; manageable safety profile reported.
- Dose expansion enrollment ongoing for both BCMA-naïve and BCMA-exposed cohorts; additional data expected in 2026.

## SEC filing metadata
- accession: 0001619856-26-000012
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/0001619856-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985626000012/crbu-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-26-000012
- JSON: https://secwatch.observer/filing/0001619856-26-000012.json
- Plain text: https://secwatch.observer/filing/0001619856-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.